Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy

Vet Comp Oncol. 2012 Sep;10(3):163-73. doi: 10.1111/j.1476-5829.2012.00342.x.

Abstract

Tyrosine kinases (TKs) are key mediators of signalling pathways in cells. Located at the surface of the cell, within the cytoplasm or in the nucleous, TKs have been showed to be involved in regulation of normal cellular processes and also play an important role in the development, progression and spread of several types of cancer. Seventy percent of TK's are Receptor Tyrosine Kinases and these have become key targets for cancer therapy. This short synopsis is intended to give the reader an introduction to this area of targeted therapy for cancer as a prelude to this special edition of Veterinary and Comparative Oncology.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Drug Therapy, Combination
  • Humans
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Neoplasms / drug therapy
  • Neoplasms / enzymology
  • Neoplasms / veterinary*
  • Piperidines
  • Pyridines
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / drug effects
  • Receptor Protein-Tyrosine Kinases / physiology
  • Thiazoles / pharmacology
  • Thiazoles / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Indoles
  • Piperidines
  • Pyridines
  • Pyrroles
  • Thiazoles
  • toceranib phosphate
  • Receptor Protein-Tyrosine Kinases
  • masitinib